Altris AI announced that it has received the CE Mark approval for its Standard Functionality for retinal conditions detection on Optical Coherence Tomography (OCT) scans. Altris AI Standard Functionality is ready for preliminary screening of retinal diseases in clinical practice. Altris AI detects retinal pathological signs of more than 30 retinal diseases and classifies them according to severities.
Altris AI Standard Functionality for OCT scans interpretation, the first of multiple Altris AI versions, is now approved for commercial sale within the European Union. Altris AI diagnostic software is based on computer vision and deep learning technologies which automatically analyzes OCT images.
“Today the biggest eye care problem is late detection of retinal diseases. Altris AI is an incredible tool for screening examinations. According to the results of our clinical validation, Altris AI Standard Functionality shows great performance for more than 30 pathologies,” Altris AI Medical Director Maria Znamenska, MD, PhD, Associate Professor of Ophthalmology, said in a company news release. “Now, not only an experienced retinologist, but optometrists and even general practitioners can detect minor retinal pathologies in early stages. Our team believes it will help to save sight for millions of people.”
“Our system allows the user to work via a web browser or as an OCT device fully integrated solution,” CEO Andrey Kuropyatnyk said in the news release. “Currently, Altris AI is integrated with Huvitz HOCT-1F device, all-in-One 3D OCT and fundus camera. Integration with OCT device means an easy, convenient and secure way to work with our system. Just in one click our system analyses all scans in the examination and represents results and data in a dynamic and informative way, even minor changes and pathologies in the retina can be detected without any compromise. Also, end-user has access to previous AI analysis results to track progression in follow-up examinations. Upcoming integrations with other OCT devices, data management, and telemedicine systems will be announced soon.”